Officials in the United States have approved a new COVID-19 antibody medication for persons with major health issues or allergies who are unable to receive appropriate protection via immunisation.
The Food and Medication Administration authorised AstraZeneca’s drug combination emergency use on Wednesday.
Cancer patients, organ transplant recipients, and persons with severe vaccine allergies may benefit from the medicine. According to health professionals, around 2% to 3% of the US population falls into this category.
Other antibody medications are used to treat COVID-19 infection or to prevent infection following probable viral exposure. The new AstraZeneca medicine is meant to be used as a long-term preventative measure rather than a therapy.
